Tags

Type your tag names separated by a space and hit enter

Fenofibrate-induced renal dysfunction, yes or no?
J Res Med Sci. 2020; 25:39.JR

Abstract

In the treatment process of hypertriglyceridemia and diabetic nephropathy in type 2 diabetes, fenofibrate (FEN) is a well-known medication. FEN is from fibrate class drugs that using orally; however, as a side effect, it is associated with serum creatinine level increasing. The aim of this review was to determine the real effect of FEN therapy on renal functions based on both experimental and clinical studies. For this review, using the keywords of "fenofibrate" and "renal" and "function," a variety of sources of information banks, including PubMed, Google Scholar, and Scopus, were used, and the published articles were considered and interpreted. Followed by searching in databases, 45 articles were collected. After screening these articles, based on the study source, they were devided into two parts: 23 articles on animal experiments and 22 articles clinical experiments. Based on this information, it seems that the protective mechanism of FEN is related to vascular endothelial functions. The increased creatinine by FEN is related to different sensitivities to FEN effects caused by a polymorphism in different patients. In patients with normal renal function, follow-up of serum creatinine would be necessary after FEN, but the discontinuation of FEN is not recommended. In addition, in diabetic patients with hypertriglyceridemia, FEN treatment would be suggested for protecting the kidney from diabetes-induced renal injury.

Authors+Show Affiliations

Water and Electrolytes Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.Water and Electrolytes Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.Isfahan Kidney Diseases Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.Water and Electrolytes Research Center, Isfahan University of Medical Sciences, Isfahan, Iran. Department of Physiology, Isfahan University of Medical Sciences, Isfahan, Iran. Isfahan MN Institute of Basic and Applied Sciences Research, Isfahan, Iran.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

32582345

Citation

Emami, Fatemeh, et al. "Fenofibrate-induced Renal Dysfunction, Yes or No?" Journal of Research in Medical Sciences : the Official Journal of Isfahan University of Medical Sciences, vol. 25, 2020, p. 39.
Emami F, Hariri A, Matinfar M, et al. Fenofibrate-induced renal dysfunction, yes or no? J Res Med Sci. 2020;25:39.
Emami, F., Hariri, A., Matinfar, M., & Nematbakhsh, M. (2020). Fenofibrate-induced renal dysfunction, yes or no? Journal of Research in Medical Sciences : the Official Journal of Isfahan University of Medical Sciences, 25, 39. https://doi.org/10.4103/jrms.JRMS_772_19
Emami F, et al. Fenofibrate-induced Renal Dysfunction, Yes or No. J Res Med Sci. 2020;25:39. PubMed PMID: 32582345.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Fenofibrate-induced renal dysfunction, yes or no? AU - Emami,Fatemeh, AU - Hariri,Amirali, AU - Matinfar,Mohammad, AU - Nematbakhsh,Mehdi, Y1 - 2020/04/13/ PY - 2019/10/12/received PY - 2019/12/16/revised PY - 2020/02/03/accepted PY - 2020/6/26/entrez PY - 2020/6/26/pubmed PY - 2020/6/26/medline KW - Creatinine KW - fenofibrate KW - renal dysfunction SP - 39 EP - 39 JF - Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences JO - J Res Med Sci VL - 25 N2 - In the treatment process of hypertriglyceridemia and diabetic nephropathy in type 2 diabetes, fenofibrate (FEN) is a well-known medication. FEN is from fibrate class drugs that using orally; however, as a side effect, it is associated with serum creatinine level increasing. The aim of this review was to determine the real effect of FEN therapy on renal functions based on both experimental and clinical studies. For this review, using the keywords of "fenofibrate" and "renal" and "function," a variety of sources of information banks, including PubMed, Google Scholar, and Scopus, were used, and the published articles were considered and interpreted. Followed by searching in databases, 45 articles were collected. After screening these articles, based on the study source, they were devided into two parts: 23 articles on animal experiments and 22 articles clinical experiments. Based on this information, it seems that the protective mechanism of FEN is related to vascular endothelial functions. The increased creatinine by FEN is related to different sensitivities to FEN effects caused by a polymorphism in different patients. In patients with normal renal function, follow-up of serum creatinine would be necessary after FEN, but the discontinuation of FEN is not recommended. In addition, in diabetic patients with hypertriglyceridemia, FEN treatment would be suggested for protecting the kidney from diabetes-induced renal injury. SN - 1735-1995 UR - https://www.unboundmedicine.com/medline/citation/32582345/Fenofibrate-induced_renal_dysfunction,_yes_or_no L2 - https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/32582345/ DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.